Macquarie Group’s Solid Biosciences SLDB Stock Holding History

Macquarie Group’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,267	Closed	-$17	–	2114
2024 Q1	$17	Buy	+1,267	New	+$11.9K	﹤0.01%	1700

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Macquarie Group's SLDB Position: Q2 2024 in Review

Macquarie Group sold out of Solid Biosciences (SLDB) in Q2 2024, closing a stake of 1,267 shares — an estimated $17 sold.

Macquarie Group first reported a position in SLDB in Q1 2024 and held it in 1 quarter. The position peaked at $17 in Q1 2024. 80 funds tracked by Wall St. Rank hold SLDB as of Q2 2024.

Macquarie Group reported no remaining Solid Biosciences position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,267 Solid Biosciences shares in Q2 2024, an estimated $17.
Macquarie Group first reported a position in Solid Biosciences in Q1 2024 and held it in 1 quarter.
Macquarie Group's Solid Biosciences position peaked at $17 in Q1 2024.
80 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.